Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Christian Ruff, MD
Advertisement
Dr Ruff is the director of general cardiology at Bringham and Women's Hospital, and also an associate professor at Harvard Medical School.
Articles by Christian Ruff, MD
Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Advertisement
Latest Updated Articles
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 TrialPublished: January 22nd 2025 | Updated:
Abelacimab Shows Unprecedented Bleeding Risk Reduction in Patients With Atrial FibrillationPublished: March 30th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
2
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
3
Physical Activity, Vaccination May Protect Against Long COVID
4
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
5
